Literature DB >> 30534831

Diabetic foot - epidemiological and histopathological aspects.

Marilena Monica Ţânţu1, George Mihail Man, Liliana Marcela Rogozea, Carmen Daniela Domnariu, Florentina Cristina Pleşa, Diana Maria Traşcă, Bogdan Virgil Cotoi, Loredana Elena Stoica, Camelia Nicolae, Roxana Maria Nemeş.   

Abstract

Our study included a total of 259 patients with diabetes, who were admitted to the Department of Plastic Surgery and Reconstructive Microsurgery of the Emergency County Hospital of Piteşti, Romania, in 2016, with the diagnosis of "diabetic foot". Of the 259 patients, 55 (21.23%) were diagnosed with type 1 diabetes, and the remaining 204 (78.77%) were diagnosed with type 2 diabetes; the ratio of type 1∕type 2 diabetes was 1∕3.7. The injuries presented by the patients were osteitis (27.81%), moist gangrene (21.62%), abscesses (18.92%), cellulitis (11.19%), various forms of fasciitis (8.88%), perforating strand (6.18%), and dry gangrene (5.4%). The disease was most commonly diagnosed in males in the rural environment. Most of the patients were in the age group of 61-70 years old. All patients were surgically treated, but 142 (54.82%) patients needed amputations of foot segments (fingers, metatarsal or tarsal bones). The histopathological and immunohistochemical study on excised fragments revealed the existence of a chronic inflammatory process formed mainly from macrophages, mast cells and CD4+ T-lymphocytes.

Entities:  

Mesh:

Year:  2018        PMID: 30534831

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  2 in total

1.  Challenges in diabetic foot treatment during pandemic of COVID-19.

Authors:  Haris Vukas; Dragan Piljic; Samra Kadić-Vukas; Dilista Piljic
Journal:  Saudi Med J       Date:  2021-02       Impact factor: 1.484

2.  Utility of Tetrahydrobiopterin Pathway in the Assessment of Diabetic Foot Ulcer: Significant and Complex Interrelations.

Authors:  Marwan Al-Nimer; Rawa Ratha; Taha Mahwi
Journal:  J Diabetes Res       Date:  2019-11-16       Impact factor: 4.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.